Cosmetic Peptides

SNAP-8 (Acetyl Octapeptide-3)

For Research Use Only. Not for Human or Veterinary Use.

Overview

SNAP-8 is Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH₂), a longer relative of Argireline. It keeps the same core sequence and adds two residues (Ala-Asp) at the C-terminus, a change studied for stronger interaction with the SNARE complex. Like Argireline it is researched as a topical neuromodulatory peptide for dynamic expression lines, and is frequently positioned as a second-generation analogue.

Chemical Profile

PropertyValue
CAS number868802-72-6
INCI nameAcetyl Octapeptide-3
Amino-acid sequenceAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂
One-letter codeAc-EEMQRRAD-NH₂
Molecular formulaC₄₃H₇₃N₁₅O₁₆S
Molecular weight1074.30 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
SNAP-8 at a glance
Class
Neuromodulatory peptide (SNARE inhibitor)
Relationship
Extended-sequence Argireline analogue
Research status
Clinical research
Typical route
Topical
Reference trade name
SNAP-8™ (Lipotec)
Key feature
Two extra C-terminal residues (Ala-Asp)

Mechanism of Action

SNAP-8 is studied on the same principle as Argireline — interfering with SNARE assembly to soften acetylcholine release at the neuromuscular junction — but the two additional C-terminal residues are investigated for a tighter interaction with the SNAP-25 region, which is the rationale usually given for calling it a second-generation peptide.

ComponentResearch description
Primary targetSNARE assembly (SNAP-25 / syntaxin / VAMP)
Inhibition modeStudied as competitive binding at the SNAP-25 N-terminal region, with reportedly higher affinity than the hexapeptide
Extended sequenceThe added Ala-Asp is investigated for improved receptor interaction
NeurotransmitterAssociated with reduced acetylcholine exocytosis
SelectivityReported to act on regulated exocytosis rather than constitutive secretion

Comparison with Argireline (sequence-level facts):

ParameterArgirelineSNAP-8
SequenceAc-EEMQRR-NH₂Ac-EEMQRRAD-NH₂
Length6 residues8 residues
Molecular weight888.5 Da1074.3 Da
Reported bindingBaselineHigher affinity (extended sequence)

Pharmacology

ParameterValue
logP−1.9 (hydrophilic)
pKa≈ 12.5 (arginine guanidinium), 4.0 (Glu / Asp)
Topical bioavailability~2–5% (usually needs liposomal or enhancer delivery)
StabilityHigh — capped N-acetyl and C-amide ends
Protein bindingLow to moderate
MetabolismProteolytic breakdown in the epidermis
Route of administrationTopical

Research Evidence

SNAP-8 is studied as a second-generation neuromodulatory peptide, usually against Argireline as the reference, in both mechanistic (preclinical) and human (clinical) work.

Advanced expression-line research

Studied where a stronger neuromodulatory effect than the hexapeptide is the goal.

Structure–activity studies

A useful case for how sequence length changes SNARE interaction in the EEMQRR family.

Formulation research

Investigated for delivery of a larger, hydrophilic peptide across the skin barrier.

Combination research

Explored alongside matrikine peptides for multi-mechanism formulations.

Preclinical research — representative models and what they investigate:

ModelResearch focusReference
Competitive binding assaySNARE-assembly interference vs the hexapeptideSchagen SK (2017, review)
Nerve–muscle preparationMuscle-contraction amplitudeGorouhi F, Maibach HI (2009)
Neuronal cell modelStimulated neurotransmitter releaseSchagen SK (2017, review)
Human skin (ex vivo)Peptide penetrationLupo MP, Cole AL (2007)

Clinical research — the types of human study in which the ingredient is examined:

Study typeEndpoints studiedReference
Topical serum / creamExpression-line and crow’s-feet appearanceGorouhi F, Maibach HI (2009)
Anti-aging formulationsOverall wrinkle severitySchagen SK (2017)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Reduced muscle-contraction amplitude (enhanced SNARE inhibition vs Argireline)neuromuscular modelsSNAP-8 literature
Reduction in expression-line appearancetopical human studyGorouhi F, Maibach HI (2009)

For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.

Formulation & Dosing Reference

ParameterValue
Typical topical concentration1–10% (w/w)
Common working range5–10%
Solubility in water≥ 50 mg/mL
Solubility in DMSO≥ 50 mg/mL
Recommended formulation pH5.0–7.0
Storage (powder)2–8°C, sealed, dry, protected from light

Safety Profile

AssessmentReported result
Acute oral toxicity (rat)LD50 > 2000 mg/kg
Dermal irritation (rabbit)Non-irritant at 10%
Ocular irritation (rabbit)Non-irritant
Skin sensitization (GPMT)Non-sensitizing
Mutagenicity (Ames)Negative
INCI statusApproved cosmetic ingredient (Acetyl Octapeptide-3)

Physicochemical Properties

PropertyValue
AppearanceWhite to off-white lyophilized powder
Solubility in water≥ 50 mg/mL
Solubility in DMSO≥ 50 mg/mL
Melting point> 200°C (decomposition)
pH (1% aqueous)5.0–6.0
Isoelectric point (pI)≈ 8.5
Net charge at pH 7≈ +1
Light sensitivityLow

Synthesis & Manufacturing

SNAP-8 is made by solid-phase peptide synthesis of the eight-residue sequence on an amide resin, with N-terminal acetylation. The longer chain and the Arg-Arg motif make coupling efficiency the main thing to optimise, and the methionine is protected against oxidation the same way as in Argireline.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinRink amide MBHA resin (C-terminal amide)
CouplingHATU / HBTU with DIPEA; double coupling for hindered residues
Side-chain protectionGlu(OtBu), Gln(Trt), Arg(Pbf), Asp(OtBu); Met unprotected
N-terminal acetylationAcetic anhydride / DIPEA after final Fmoc removal
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5), with scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 5–30% B over 20 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 1075 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 1075 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 5–30% B over 20 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 1075 Da). Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 25°C, dark≥ 12 months< 2% degradation
Aqueous solution pH 5.5, 4°C7–14 daysMinor degradation
Aqueous solution pH 5.5, 25°C7 days< 5% degradation
Formulated serum / cream (25°C)12+ monthsPeptide largely retained
Light exposure (ICH Q1B)1.2 M lux·hLight-stable
Freeze–thaw3 cyclesAcceptable
pH stress (pH 3 or pH 8)7 daysFaster degradation outside pH 5–7
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Aspartimide formation at the aspartate and oxidation of the methionine are the main solution-phase degradation routes.

Selected References

Representative peer-reviewed literature on neuromodulatory cosmetic peptides. Listed for research reference.

  • Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 2002.
  • Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
  • Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
  • Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; end-group modifications verified
  • Research samples through to bulk, with worldwide delivery
  • Custom sequences and packaging on request

Need SNAP-8 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote